AR038276A1 - Metodos para incrementar la formacion osea. - Google Patents

Metodos para incrementar la formacion osea.

Info

Publication number
AR038276A1
AR038276A1 ARP030100043A ARP030100043A AR038276A1 AR 038276 A1 AR038276 A1 AR 038276A1 AR P030100043 A ARP030100043 A AR P030100043A AR P030100043 A ARP030100043 A AR P030100043A AR 038276 A1 AR038276 A1 AR 038276A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroalkyl
hydrogen
heterocyclic
cycloalkyl
Prior art date
Application number
ARP030100043A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR038276A1 publication Critical patent/AR038276A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Uso de inhibidores de la sintasa quinasa-3b de glucógeno para aumentar la formación ósea. Reivindicación 9: El uso o método de acuerdo con cualquiera de las reivindicaciones 1 a 8, en el cual el inhibidor de GSK-3b es un compuesto representado por la Fórmula (1), en la cual: R1 y R2 representan independientemente hidrógeno, alquilo, halo, haloalquilo, alquiltio, hidroxi, alcoxi, ciano, nitro, amino, acilamino, monoalquilamino, o dialquilamino; R3 representa hidrógeno, alquilo, cicloalquilo, heteroalquilo, -COR7 (en donde R7 es hidrógeno o alquilo), o fenilo optativamente sustituido con uno o dos sustituyentes independientemente seleccionados entre el grupo que consiste en hidrógeno, alquilo, haloalquilo, alquiltio, hidroxi, alcoxi, ciano, nitro, amino, acilamino, monoalquilamino y dialquilamino; R4 y R5 representan independientemente hidrógeno, alquilo, halo, haloalquilo, alquiltio, hidroxi, alcoxi, ciano, nitro, amino, acilamino, monoalquilamino o dialquilamino; R6 es heteroalquilo, heterociclico, heterociclialquilo, heterociclico sustituido con heteroalquilo, cicloalquilo sustituido con heteroalquilo, cicloalquilo hetereosustituido, -OR8, -S(O)nR8 (en donde n es 0 a 2; y R8 es heteroalquilo, heteroaralquilo, heterociclico o heterociclialquilo), -NR9R10 (en donde R9 es hidrógeno o alquilo y R10 es heteroalquilo, heteroaralquilo, cicloalquilo heterosustituido, heterociclilo o heterociclialquilo) o -X- (alquilen)-Y-Z (en donde X es un enlace covalente, o, -NH- ó -S(O)n1- donde n1 es 0 a 2, e Y es -O-, -NH- ó -S- y Z es heteroalquilo o SiR11R12R13 donde R11, R12 y R13 son independientemente hidrógeno o alquilo) o R6 junto con R4 forma un grupo metilendioxi o etilendioxi cuando son adyacentes entre sí; o su sal farmacéuticamente aceptable.
ARP030100043A 2002-01-10 2003-01-08 Metodos para incrementar la formacion osea. AR038276A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34805502P 2002-01-10 2002-01-10

Publications (1)

Publication Number Publication Date
AR038276A1 true AR038276A1 (es) 2005-01-12

Family

ID=23366458

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100043A AR038276A1 (es) 2002-01-10 2003-01-08 Metodos para incrementar la formacion osea.

Country Status (10)

Country Link
US (1) US7476676B2 (es)
EP (1) EP1465610B1 (es)
JP (1) JP4237066B2 (es)
CN (1) CN100409840C (es)
AR (1) AR038276A1 (es)
AU (1) AU2003235798A1 (es)
CA (1) CA2471565C (es)
DE (1) DE60325551D1 (es)
ES (1) ES2316756T3 (es)
WO (1) WO2003057202A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039485A2 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
US20050064044A1 (en) * 2003-09-19 2005-03-24 Georges Rawadi GSK-3beta inhibitors in the treatment of bone-related diseases
US20050171015A1 (en) * 2003-10-31 2005-08-04 Crabtree Gerald R. Methods and agents for enhancing bone formation or preventing bone loss
WO2006061212A1 (en) 2004-12-08 2006-06-15 Johannes Gutenberg-Universität Mainz 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
US7670742B2 (en) 2005-03-15 2010-03-02 Ricoh Company, Ltd. Recording material, toner, liquid developer and image forming method using the same
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP1757607A1 (en) 2005-08-24 2007-02-28 Molisa GmbH N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
ES2446269T3 (es) * 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
US20100137330A1 (en) * 2007-03-08 2010-06-03 Ratan Bhat Use
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
KR20120120307A (ko) 2010-01-19 2012-11-01 아스트라제네카 아베 피라진 유도체
CN104277004B (zh) 2010-09-08 2016-08-24 住友化学株式会社 制备哒嗪酮化合物的方法和其中间体
JP5885206B2 (ja) * 2010-09-15 2016-03-15 江崎グリコ株式会社 グリコーゲンを含有する骨形成促進剤
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN113248472B (zh) * 2020-02-12 2022-06-28 中国药科大学 抗骨质疏松化合物及其衍生物，药物组合物、制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4533534B2 (ja) * 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
ATE284387T1 (de) * 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
EP1196390A2 (en) * 2000-02-05 2002-04-17 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
NZ514583A (en) * 2000-02-05 2004-05-28 Vertex Pharma Pyrazole compositions useful as inhibitors of ERK
CA2417277A1 (en) * 2000-07-27 2002-02-07 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta.
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof

Also Published As

Publication number Publication date
JP2005519056A (ja) 2005-06-30
WO2003057202A1 (en) 2003-07-17
ES2316756T3 (es) 2009-04-16
AU2003235798A8 (en) 2003-07-24
EP1465610B1 (en) 2008-12-31
AU2003235798A1 (en) 2003-07-24
CN100409840C (zh) 2008-08-13
WO2003057202A8 (en) 2003-12-11
CN1703207A (zh) 2005-11-30
DE60325551D1 (de) 2009-02-12
CA2471565C (en) 2009-10-27
US7476676B2 (en) 2009-01-13
CA2471565A1 (en) 2003-07-17
JP4237066B2 (ja) 2009-03-11
EP1465610A1 (en) 2004-10-13
US20030176484A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
AR038276A1 (es) Metodos para incrementar la formacion osea.
CO6160235A2 (es) Isoxazolinas insecticidas
ECSP066695A (es) Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1
BRPI0506817A (pt) inibidores seletivos de quinase
ECSP077171A (es) Inhibidores de polimerasa viral
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
CR7950A (es) Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas
CO5690607A2 (es) Compuestos de piridina como inhibidores de dipeptidil peptidasa iv
RS20050329A (en) Selected cgrp antagonists,method for production and use thereof as medicament
AR033989A1 (es) Un compuesto derivado de la 3-indolil-4-fenil-1h-pirrol-2,5-diona, un metodo para prepararlo, y un medicamento que lo contiene
CO5590894A2 (es) Derivados de a-(n-sulfonamido)acetamida como inhibidores del peptido b-amiloideo
DE602004017126D1 (de) Acylsulfonamid-verbindungen als inhibitoren der rna-abhängigen rna-polymerase
RS20050311A (en) Selected cgrp antagonists,method for production and use thereof as medicament
AR092490A2 (es) Indolil alquil amino derivados sustituidos como inhibidores de la histona desacetilasa
EA200600594A1 (ru) Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
MY144718A (en) Viral polymerase inhibitors.
PE20091371A1 (es) Inhibidores de hsp90
CY1107846T1 (el) Παραγωγα κιναζολινονης χρησιμα ως βανιλλοειδεις ανταγωνιστες
AR052559A1 (es) Derivados de pirazol para inhibir cdk's y gsk's
AR049883A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
AR040412A1 (es) Derivados de sulfamato sustituido como anticonvulsivo
EA200870192A1 (ru) Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
NO20064175L (no) Heterosyklisk forbindelse
HN2005000239A (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica
EA201170595A1 (ru) ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА

Legal Events

Date Code Title Description
FB Suspension of granting procedure